dc.contributor.author
Aberer, Werner
dc.contributor.author
Maurer, Marcus
dc.contributor.author
Bouillet, Laurence
dc.contributor.author
Zanichelli, Andrea
dc.contributor.author
Caballero, Teresa
dc.contributor.author
Longhurst, Hilary J.
dc.contributor.author
Perrin, Amandine
dc.contributor.author
Andresen, Irmgard
dc.date.accessioned
2018-06-08T10:18:39Z
dc.date.available
2017-09-01T08:42:00.029Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20225
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-23530
dc.description.abstract
Background Patients with hereditary angioedema (HAE) due to C1-inhibitor
deficiency (C1-INH-HAE) experience recurrent attacks of cutaneous or
submucosal edema that may be frequent and severe; prophylactic treatments can
be prescribed to prevent attacks. However, despite the use of long-term
prophylaxis (LTP), breakthrough attacks are known to occur. We used data from
the Icatibant Outcome Survey (IOS) to evaluate the characteristics of
breakthrough attacks and the effectiveness of icatibant as a treatment option.
Methods Data on LTP use, attacks, and treatments were recorded. Attack
characteristics, treatment characteristics, and outcomes (time to treatment,
time to resolution, and duration of attack) were compared for attacks that
occurred with versus without LTP. Results Data on 3228 icatibant-treated
attacks from 448 patients with C1-INH-HAE were analyzed; 30.1% of attacks
occurred while patients were using LTP. Attack rate, attack severity, and the
distribution of attack sites were similar across all types of LTP used, and
were comparable to the results found in patients who did not receive LTP.
Attacks were successfully treated with icatibant; 82.5% of all breakthrough
attacks were treated with a single icatibant injection without C1-INH rescue
medication. Treatment outcomes were comparable for breakthrough attacks across
all LTP types, and for attacks without LTP. Conclusions Patients who use LTP
should be aware that breakthrough attacks can occur, and such attacks can be
severe. Thus, patients with C1-INH-HAE using LTP should have emergency
treatment readily available. Data from IOS show that icatibant is effective
for the treatment of breakthrough attacks. Trial Registration NCT01034969
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Hereditary angioedema Icatibant Breakthrough attacks Prophylaxis Bradykinin
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Breakthrough attacks in patients with hereditary angioedema receiving long-
term prophylaxis are responsive to icatibant
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Allergy, Asthma & Clinical Immunology. - 13 (2017), Artikel Nr. 31
dc.title.subtitle
findings from the Icatibant Outcome Survey
dcterms.bibliographicCitation.doi
10.1186/s13223-017-0203-z
dcterms.bibliographicCitation.url
http://doi.org/10.1186/s13223-017-0203-z
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000027762
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000008681
dcterms.accessRights.openaire
open access